Financial Survey: NexImmune (OTCMKTS:NEXI) and Hillstream Biopharma (NASDAQ:CNTN)

Hillstream Biopharma (NASDAQ:CNTN) and NexImmune (OTCMKTS:NEXI) are both manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Hillstream Biopharma and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
NexImmune	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Hillstream Biopharma and NexImmune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
NexImmune	0	0	0	0	0.00

Given NexImmune’s higher possible upside, analysts clearly believe NexImmune is more favorable than Hillstream Biopharma.

Earnings and Valuation

This table compares Hillstream Biopharma and NexImmune”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92 million	($1.15)	-2.00
NexImmune	N/A	N/A	-$32.34 million	($18.29)	N/A

Hillstream Biopharma is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, NexImmune has a beta of -1922.25, suggesting that its share price is 192,325% less volatile than the S&P 500.

Institutional and Insider Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 14.9% of NexImmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

NexImmune beats Hillstream Biopharma on 6 of the 9 factors compared between the two stocks.

About Hillstream Biopharma

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.